

Classification of small molecule protein kinase inhibitors and their drug-enzyme complexes

Pharmacological Research

103, 26-48

DOI: 10.1016/j.phrs.2015.10.021

Citation Report

#	ARTICLE	IF	CITATIONS
2	Kinases inhibitors and small molecules: A new treatment tool for axial spondyloarthritis. Joint Bone Spine, 2016, 83, 473-475.	1.6	3
3	Inherent formulation issues of kinase inhibitors. Journal of Controlled Release, 2016, 239, 118-127.	9.9	20
4	Discovery and Characterization of Allosteric WNK Kinase Inhibitors. ACS Chemical Biology, 2016, 11, 3338-3346.	3.4	38
5	Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation. Molecular BioSystems, 2016, 12, 3146-3165.	2.9	25
6	From Type I to Type II: Design, Synthesis, and Characterization of Potent Pyrazinones as DFG-Out Inhibitors of PDGFR β . ChemMedChem, 2016, 11, 2664-2674.	3.2	3
7	Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacological Research, 2016, 113, 395-408.	7.1	70
8	Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacological Research, 2016, 111, 784-803.	7.1	279
9	Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells. Archiv Der Pharmazie, 2016, 349, 925-933.	4.1	7
10	Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 1-25.	0.1	0
11	Determination of structural requirements of Mer kinase inhibitors and binding interaction analysis using in silico approaches. Medicinal Chemistry Research, 2016, 25, 3021-3029.	2.4	2
12	Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors. Journal of Molecular Graphics and Modelling, 2016, 70, 275-283.	2.4	9
13	Biophysical investigation and conformational analysis of p38 α kinase inhibitor doramapimod and its analogues. MedChemComm, 2016, 7, 1421-1428.	3.4	4
14	Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacological Research, 2016, 107, 249-275.	7.1	179
15	Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. Expert Review of Clinical Pharmacology, 2016, 9, 525-539.	3.1	2
16	Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacological Research, 2017, 117, 343-356.	7.1	87
17	Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis. Immunotherapy, 2017, 9, 221-223.	2.0	3
18	Do Fragments and Crystallization Additives Bind Similarly to Drug-like Ligands?. Journal of Chemical Information and Modeling, 2017, 57, 1197-1209.	5.4	14
19	ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacological Research, 2017, 121, 202-212.	7.1	93

#	ARTICLE	IF	CITATIONS
20	Discovery of ^{wt} RET and ^{V804M} RET Inhibitors: From Hit to Lead. ChemMedChem, 2017, 12, 1390-1398.	3.2	7
21	Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 726-731.	2.8	31
22	Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacological Research, 2017, 120, 116-132.	7.1	184
23	Structure-Based Design of Tricyclic NF- κ B Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K). Journal of Medicinal Chemistry, 2017, 60, 627-640.	6.4	51
24	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacological Research, 2017, 117, 20-31.	7.1	78
25	FIKK Kinase, a Ser/Thr Kinase Important to Malaria Parasites, Is Inhibited by Tyrosine Kinase Inhibitors. ACS Omega, 2017, 2, 6605-6612.	3.5	16
26	Imidazo[1,2- <i>a</i>]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5221-5224.	2.2	8
27	In silico studies on 2-substituted phenol quinazoline derivatives as RET receptor tyrosine kinase antagonists. Medicinal Chemistry Research, 2017, 26, 3228-3239.	2.4	4
28	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nature Reviews Clinical Oncology, 2017, 14, 735-748.	27.6	234
29	The anthraquinone emodin inhibits the non-exported FIKK kinase from Plasmodium falciparum. Bioorganic Chemistry, 2017, 75, 217-223.	4.1	11
30	Network-based modelling and percolation analysis of conformational dynamics and activation in the CDK2 and CDK4 proteins: dynamic and energetic polarization of the kinase lobes may determine divergence of the regulatory mechanisms. Molecular BioSystems, 2017, 13, 2235-2253.	2.9	7
31	How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. European Journal of Medicinal Chemistry, 2017, 142, 131-151.	5.5	46
32	Pyrrolo[2,3- <i>d</i>]pyrimidines active as Btk inhibitors. Expert Opinion on Therapeutic Patents, 2017, 27, 1305-1318.	5.0	9
33	Kinase Crystal Miner: A Powerful Approach to Repurposing 3D Hinge Binding Fragments and Its Application to Finding Novel Bruton Tyrosine Kinase Inhibitors. Journal of Chemical Information and Modeling, 2017, 57, 2152-2160.	5.4	13
34	The Story of Kinase Inhibitors Development with Special Reference to Allosteric Site. , 2017, , 57-68.		2
35	Drug Design: Principles and Applications. , 2017, , .		5
36	Germinalâ€center kinaseâ€like kinase coâ€crystal structure reveals a swapped activation loop and Câ€terminal extension. Protein Science, 2017, 26, 152-162.	7.6	16
37	Approved and Experimental Smallâ€Molecule Oncology Kinase Inhibitor Drugs: A Midâ€2016 Overview. Medicinal Research Reviews, 2017, 37, 314-367.	10.5	65

#	ARTICLE	IF	CITATIONS
38	MicroRNAs Associated with Von Hippelâ€“Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences, 2017, 18, 2495.	4.1	37
39	The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment. Molecules, 2017, 22, 1411.	3.8	23
40	Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. Cancers, 2017, 9, 87.	3.7	53
41	Kinase-Centric Computational Drug Development. Annual Reports in Medicinal Chemistry, 2017, , 197-236.	0.9	9
42	Kinase Inhibitors. , 2017, , 57-80.		0
43	Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome. PLoS ONE, 2017, 12, e0179936.	2.5	34
44	Ensemble-based modeling and rigidity decomposition of allosteric interaction networks and communication pathways in cyclin-dependent kinases: Differentiating kinase clients of the Hsp90-Cdc37 chaperone. PLoS ONE, 2017, 12, e0186089.	2.5	17
45	Discovery of 7-Oxo-2,4,5,7-tetrahydro-6<i>H</i>-pyrazolo[3,4- <i>c</i>]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structureâ€“Kinetic Relationships. Journal of Medicinal Chemistry, 2018, 61, 2384-2409.</i>	6.4	78
46	Lapatinib nano-delivery systems: a promising future for breast cancer treatment. Expert Opinion on Drug Delivery, 2018, 15, 495-507.	5.0	33
48	Hypoxia-selective allosteric destabilization of activin receptor-like kinases: A potential therapeutic avenue for prophylaxis of heterotopic ossification. Bone, 2018, 112, 71-89.	2.9	10
49	Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 577-583.	2.2	17
50	The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharmacological Research, 2018, 129, 65-83.	7.1	117
51	Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacological Research, 2018, 128, 1-17.	7.1	91
52	Marine-derived protein kinase inhibitors for neuroinflammatory diseases. BioMedical Engineering OnLine, 2018, 17, 46.	2.7	24
53	KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking. Journal of Cheminformatics, 2018, 10, 20.	6.1	6
54	The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacological Research, 2018, 133, 35-52.	7.1	66
55	AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965. Journal of Biological Chemistry, 2018, 293, 8874-8885.	3.4	98
56	Exploration and Comparison of the Geometrical and Physicochemical Properties of an Î±C Allosteric Pocket in the Structural Kinome. Journal of Chemical Information and Modeling, 2018, 58, 1094-1103.	5.4	9

#	ARTICLE	IF	CITATIONS
57	The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients. <i>Scientific Reports</i> , 2018, 8, 5295.	3.3	22
58	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasetib (ABT-348) in a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2018, 118, 1042-1050.	6.4	27
59	Design of potent Bâ€Raf^{V600E} inhibitors by multiple copy simulation search strategy. <i>Chemical Biology and Drug Design</i> , 2018, 91, 567-574.	3.2	6
60	Comparative evaluation of electrospraying and lyophilization techniques on solid state properties of Erlotinib nanocrystals: Assessment of In-vitro cytotoxicity. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 111, 257-269.	4.0	29
61	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical researchâ€™practice gaps, challenges, and insights. <i>Medicinal Research Reviews</i> , 2018, 38, 325-376.	10.5	50
62	Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 151-167.	27.6	247
63	A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. <i>Blood</i> , 2018, 131, 426-438.	1.4	104
64	A Comprehensive Structural Overview of p38Î± Mitogenâ€™Activated Protein Kinase in Complex with ATPâ€™Site and Nonâ€™ATPâ€™Site Binders. <i>ChemMedChem</i> , 2018, 13, 7-14.	3.2	20
65	Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules. <i>Journal of Chemical Information and Modeling</i> , 2018, 58, 68-89.	5.4	5
66	CAR-T cells and combination therapies: Whatâ€™s next in the immunotherapy revolution?. <i>Pharmacological Research</i> , 2018, 129, 194-203.	7.1	33
67	Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy. <i>Applied Biochemistry and Biotechnology</i> , 2018, 185, 289-315.	2.9	10
68	Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 422-443.	6.4	35
69	Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38Î±. <i>Chemical Communications</i> , 2018, 54, 12057-12060.	4.1	10
70	RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. <i>Cancer Cell</i> , 2018, 34, 757-774.e7.	16.8	170
71	Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia. <i>Paediatric Drugs</i> , 2018, 20, 593-600.	3.1	19
72	Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer. <i>Cancer Biology and Medicine</i> , 2018, 15, 375.	3.0	22
73	Structural Basis for the Inhibition of Cyclin Gâ€™Associated Kinase by Gefitinib. <i>ChemistryOpen</i> , 2018, 7, 713-719.	1.9	15
74	Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6. <i>Scientific Reports</i> , 2018, 8, 16047.	3.3	26

#	ARTICLE	IF	CITATIONS
75	Redefining the Protein Kinase Conformational Space with Machine Learning. <i>Cell Chemical Biology</i> , 2018, 25, 916-924.e2.	5.2	65
76	Determination of Amino Acid Residues Responsible for Specific Interaction of Protein Kinases with Small Molecule Inhibitors. <i>Molecular Biology</i> , 2018, 52, 478-487.	1.3	4
77	Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF- κ B Inducing Kinase. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6801-6813.	6.4	38
78	Synthesis and molecular modelling studies of pyrimidinones and pyrrolo[3,4-d]-pyrimidinodiones as new antiplasmodial compounds. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2018, 113, e170452.	1.6	6
79	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. <i>International Journal of Molecular Sciences</i> , 2018, 19, 732.	4.1	29
80	Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. <i>EMBO Journal</i> , 2018, 37, .	7.8	55
81	Dissection of Protein Kinase Pathways in Live Cells Using Photoluminescent Probes: Surveillance or Interrogation?. <i>Chemosensors</i> , 2018, 6, 19.	3.6	2
82	Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics. <i>Current Opinion in Chemical Biology</i> , 2018, 44, 101-109.	6.1	20
83	Insights into the Impact of Linker Flexibility and Fragment Ionization on the Design of CK2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 111.	4.1	2
84	PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials. <i>Molecules</i> , 2018, 23, 908.	3.8	124
85	Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology. <i>Biochimie</i> , 2018, 152, 188-197.	2.6	11
86	Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. <i>Cell Systems</i> , 2018, 7, 161-179.e14.	6.2	53
87	Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 84, 189-196.	2.4	4
88	Kinase-targeted cancer therapies: progress, challenges and future directions. <i>Molecular Cancer</i> , 2018, 17, 48.	19.2	796
89	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. <i>Pharmacological Research</i> , 2018, 135, 239-258.	7.1	154
90	Characterization of Protein Kinase ULK3 Regulation by Phosphorylation and Inhibition by Small Molecule SU6668. <i>Biochemistry</i> , 2018, 57, 5456-5465.	2.5	6
91	Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β -cell proliferation activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1005-1016.	5.5	36
92	Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8120-8135.	6.4	275

#	ARTICLE	IF	CITATIONS
93	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies â€“ Part 2. Expert Opinion on Drug Safety, 2018, 17, 893-915.	2.4	8
94	Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials. European Journal of Medicinal Chemistry, 2018, 155, 445-458.	5.5	13
95	Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- <i>d</i>]pyrimidine-2,4(1 <i>H</i>),3 <i>H</i>)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. Journal of Medicinal Chemistry, 2018, 61, 5609-5622.	6.4	27
96	Deathâ€“associated protein kinase (DAPK) family modulators: Current and future therapeutic outcomes. Medicinal Research Reviews, 2019, 39, 349-385.	10.5	80
97	Structure-Based Virtual Screening of High-Affinity ATP-Competitive Inhibitors Against Human Lemur Tyrosine Kinase-3 (LMTK3) Domain: A Novel Therapeutic Target for Breast Cancer. Interdisciplinary Sciences, Computational Life Sciences, 2019, 11, 527-541.	3.6	10
98	Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2019, 24, 133-152.	2.4	20
99	Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity. Scientific Reports, 2019, 9, 11390.	3.3	18
100	A patent review of RAF kinase inhibitors (2010â€“2018). Expert Opinion on Therapeutic Patents, 2019, 29, 675-688.	5.0	13
101	NTRK-Fusions â€“ A new kid on the block. Pathology Research and Practice, 2019, 215, 152572.	2.3	17
102	Implementation of pharmacophore-based 3D QSAR model and scaffold analysis in order to excavate pristine ALK inhibitors. Medicinal Chemistry Research, 2019, 28, 1726-1739.	2.4	3
103	Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors InÂŽVitro. Journal of Thoracic Oncology, 2019, 14, 1753-1765.	1.1	105
104	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLUâ€“285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British Journal of Haematology, 2019, 187, 488-501.	2.5	30
105	RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress. Clinical Science, 2019, 133, 1609-1627.	4.3	61
106	Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques. Bioorganic Chemistry, 2019, 91, 103125.	4.1	9
107	Data-driven computational analysis of allosteric proteins by exploring protein dynamics, residue coevolution and residue interaction networks. Biochimica Et Biophysica Acta - General Subjects, 2019, , .	2.4	17
108	Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?. International Journal of Molecular Sciences, 2019, 20, 3429.	4.1	39
109	Rapid Screen for Tyrosine Kinase Inhibitor Resistance Mutations and Substrate Specificity. ACS Chemical Biology, 2019, 14, 1888-1895.	3.4	8
110	<p>Novel approaches to treating advanced systemic mastocytosis</p>. Clinical Pharmacology: Advances and Applications, 2019, Volume 11, 77-92.	1.2	26

#	ARTICLE	IF	CITATIONS
111	Kinase Chemodiversity from the Arctic: The Breitfussins. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10167-10181.	6.4	20
112	Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126624.	2.2	5
113	Protein Allostery in Drug Discovery. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	1.6	11
114	The Novel Serine/Threonine Protein Kinase LmjF.22.0810 from <i>Leishmania major</i> may be Involved in the Resistance to Drugs such as Paromomycin. <i>Biomolecules</i> , 2019, 9, 723.	4.0	8
115	New 2,4-disubstituted-2-thiopyrimidines as VEGFR ² inhibitors: Design, synthesis, and biological evaluation. <i>Archiv Der Pharmazie</i> , 2019, 352, e1900089.	4.1	12
117	Three-Dimensional Visualization of Kinase Inhibitors as Therapeutically Relevant Examples To Reinforce Types of Enzyme Inhibitors. <i>Journal of Chemical Education</i> , 2019, 96, 296-303.	2.3	1
118	HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 533-566.	6.1	114
119	A Novel Conjugate of Bis[² -(4-bromophenyl)amino]quinazoline], a EGFR-TK Ligand, with a Fluorescent Ru(II)-Bipyridine Complex Exhibits Specific Subcellular Localization in Mitochondria. <i>Molecular Pharmaceutics</i> , 2019, 16, 4260-4273.	4.6	16
120	Drug Repurposing for Paracoccidioidomycosis Through a Computational Chemogenomics Framework. <i>Frontiers in Microbiology</i> , 2019, 10, 1301.	3.5	11
121	Lead identification and characterization of hTrkA type 2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126680.	2.2	5
122	Conformational restriction of a type II FMS inhibitor leading to discovery of 5-methyl-N-(2-aryl-1H-benzo[d]imidazo-5-yl)isoxazole-4-carboxamide analogues as selective FLT3 inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1716-1721.	5.2	8
123	Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). <i>Journal of Biological Chemistry</i> , 2019, 294, 4511-4519.	3.4	14
124	Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation. <i>Chemical Biology and Drug Design</i> , 2019, 93, 934-948.	3.2	15
125	Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. <i>Journal of Biological Chemistry</i> , 2019, 294, 10428-10437.	3.4	43
126	Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 707-722.	5.5	36
127	KRAS ^{G12C} inhibition produces a driver-limited state revealing collateral dependencies. <i>Science Signaling</i> , 2019, 12, .	3.6	123
128	Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6512-6524.	6.4	52
129	Targeting ERK beyond the boundaries of the kinase active site in melanoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 1551-1570.	2.7	26

#	ARTICLE	IF	CITATIONS
130	Role of JAK inhibitors and immune cells in transplantation. Cytokine and Growth Factor Reviews, 2019, 47, 62-73.	7.2	4
131	Protein post-translational modifications – A challenge for bioelectrochemistry. TrAC - Trends in Analytical Chemistry, 2019, 116, 44-60.	11.4	15
132	Deciphering the Allosteric Binding Mechanism of the Human Tropomyosin Receptor Kinase A (TrkA) Inhibitors. ACS Chemical Biology, 2019, 14, 1205-1216.	3.4	16
133	Targeting RIPK1 for the treatment of human diseases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9714-9722.	7.1	258
134	Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases. ACS Chemical Biology, 2019, 14, 1249-1259.	3.4	20
135	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10009-10018.	7.1	46
136	Discovery of novel anaplastic lymphoma kinase inhibitors: Structure and energy-based pharmacophore strategy. Journal of Theoretical and Computational Chemistry, 2019, 18, 1950014.	1.8	3
137	A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance. Protein Journal, 2019, 38, 142-150.	1.6	3
138	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor. ACS Medicinal Chemistry Letters, 2019, 10, 780-785.	2.8	48
139	Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research, 2019, 144, 19-50.	7.1	377
140	Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. Journal of Medicinal Chemistry, 2019, 62, 3886-3897.	6.4	23
141	Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer. Cells, 2019, 8, 316.	4.1	35
142	Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors. Journal of the American Chemical Society, 2019, 141, 6553-6560.	13.7	80
143	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacological Research, 2019, 142, 151-168.	7.1	202
144	Development of a UHPLC-MS method for inhibitor screening against α -L-1,3-fucosidase. Analytical and Bioanalytical Chemistry, 2019, 411, 1467-1477.	3.7	2
145	Accelerating Lead Identification by High Throughput Virtual Screening: Prospective Case Studies from the Pharmaceutical Industry. Journal of Chemical Information and Modeling, 2019, 59, 2046-2062.	5.4	24
146	Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egyptian Journal of Medical Human Genetics, 2019, 20, .	1.0	62
147	Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors. PLoS ONE, 2019, 14, e0225132.	2.5	4

#	ARTICLE	IF	CITATIONS
148	Discovering novel P38 β inhibitors for the treatment of prostate cancer through virtual screening methods. <i>Future Medicinal Chemistry</i> , 2019, 11, 3125-3137.	2.3	4
150	Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors. <i>European Biophysics Journal</i> , 2019, 48, 73-82.	2.2	11
151	Novel FRET-Based Src Biosensor Reveals Mechanisms of Src Activation and Its Dynamics in Focal Adhesions. <i>Cell Chemical Biology</i> , 2019, 26, 255-268.e4.	5.2	14
152	Evolution of Small Molecule Kinase Drugs. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 153-160.	2.8	27
153	Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 875-892.	6.4	20
154	Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer. <i>Computational Biology and Chemistry</i> , 2019, 78, 290-296.	2.3	4
155	Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. <i>Pharmacological Research</i> , 2019, 139, 395-411.	7.1	315
156	Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 37-53.	5.5	56
157	Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy. <i>Journal of Molecular Modeling</i> , 2019, 25, 13.	1.8	3
158	Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma. <i>Oncogene</i> , 2019, 38, 2994-3002.	5.9	13
159	Discovery of highly potent V600E-B-Raf kinase inhibitors: Molecular modeling study. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 655-663.	3.0	8
160	Fibroblast growth factor receptors as treatment targets in clinical oncology. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 105-122.	27.6	227
161	Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles. <i>Seminars in Cancer Biology</i> , 2019, 56, 149-167.	9.6	23
162	Elucidation of conformational diversity of druggable enzymes and classification of chemical modulators based on inhibitor-bound structures. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 4563-4568.	3.5	2
163	Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. <i>Pharmacological Research</i> , 2019, 139, 471-488.	7.1	270
164	Computational insights into the interaction of small molecule inhibitors with HRI kinase domain. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 1715-1723.	3.5	4
165	Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 266-271.	2.8	28
166	Recent advance in the development of novel, selective and potent FGFR inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111884.	5.5	39

#	ARTICLE	IF	CITATIONS
167	Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors. <i>Applied Biochemistry and Biotechnology</i> , 2020, 190, 1127-1146.	2.9	12
168	Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129448.	2.4	13
169	Renaissance of Allostery to Disrupt Protein Kinase Interactions. <i>Trends in Biochemical Sciences</i> , 2020, 45, 27-41.	7.5	36
170	New Promise and Opportunities for Allosteric Kinase Inhibitors. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 13764-13776.	13.8	109
171	Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. <i>Pharmacological Research</i> , 2020, 152, 104609.	7.1	415
172	Rational Drug Design of Axl Tyrosine Kinase Type I Inhibitors as Promising Candidates Against Cancer. <i>Frontiers in Chemistry</i> , 2019, 7, 920.	3.6	9
173	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. <i>Future Oncology</i> , 2020, 16, 4251-4264.	2.4	43
174	Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer. , 2020, 207, 107454.		21
175	The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. <i>Pharmacological Research</i> , 2020, 151, 104567.	7.1	88
176	Structural Characterization of the Aurora Kinase B â€œDFG-flipâ€•Using Metadynamics. <i>AAPS Journal</i> , 2020, 22, 14.	4.4	13
177	Molecular Modeling of Protein Kinases: Current Status and Challenges. <i>Topics in Medicinal Chemistry</i> , 2020, , 25-41.	0.8	0
178	Discovery of anaplastic lymphoma kinase inhibitors from natural product library: A holistic in silico approach. <i>Biotechnology and Applied Biochemistry</i> , 2020, , .	3.1	0
179	Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 242.	3.4	28
180	Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019). <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112640.	5.5	62
181	Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance. <i>Pharmacological Reports</i> , 2020, 72, 799-813.	3.3	39
182	Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12403-12428.	6.4	48
183	Next Generation Kinase Inhibitors. , 2020, , .		8
184	Compounds from Natural Sources as Protein Kinase Inhibitors. <i>Biomolecules</i> , 2020, 10, 1546.	4.0	37

#	ARTICLE	IF	CITATIONS
185	Mechanisms of EGFR Resistance in Glioblastoma. International Journal of Molecular Sciences, 2020, 21, 8471.	4.1	36
186	Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2020, 63, 14609-14625.	6.4	30
187	Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2020, 206, 112691.	5.5	16
188	Expression and purification of the extracellular domain of wild-type humanRET and the dimeric oncogenic mutant C634R. International Journal of Biological Macromolecules, 2020, 164, 1621-1630.	7.5	1
189	Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB. Molecules, 2020, 25, 3226.	3.8	40
190	Diaminoimidazopyrimidines: Access via the Groebke–Blackburn–Bienaymé Reaction and Structural Data Mining. European Journal of Organic Chemistry, 2020, 2020, 5601-5605.	2.4	8
191	Interaction of the small-molecule kinase inhibitors tofacitinib and lapatinib with membranes. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183414.	2.6	8
192	HGF/MET Signaling in Malignant Brain Tumors. International Journal of Molecular Sciences, 2020, 21, 7546.	4.1	21
193	Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough. Biomedicine and Pharmacotherapy, 2020, 132, 110901.	5.6	2
194	Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. European Journal of Medicinal Chemistry, 2020, 208, 112752.	5.5	50
195	Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors. Cancers, 2020, 12, 2327.	3.7	10
196	Revealing the Unbinding Kinetics and Mechanism of Type I and Type II Protein Kinase Inhibitors by Local-Scaled Molecular Dynamics Simulations. Journal of Chemical Theory and Computation, 2020, 16, 6620-6632.	5.3	7
197	Achieving High Levels of Selectivity for Kinase Inhibitors. Topics in Medicinal Chemistry, 2020, , 95-123.	0.8	0
198	Positioning of an unprecedented spiro[5.5]undeca ring system into kinase inhibitor space. Scientific Reports, 2020, 10, 21265.	3.3	5
199	c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases. International Journal of Molecular Sciences, 2020, 21, 9677.	4.1	28
200	HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability. Journal of Medicinal Chemistry, 2020, 63, 15906-15945.	6.4	15
201	NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Communications Biology, 2020, 3, 776.	4.4	34
202	Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity. Biochemistry and Biophysics Reports, 2020, 24, 100838.	1.3	3

#	ARTICLE	IF	CITATIONS
203	Regorafenib analogues and their ferrocenic counterparts: synthesis and biological evaluation. <i>New Journal of Chemistry</i> , 2020, 44, 19723-19733.	2.8	2
204	Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7878.	4.1	3
205	KinFragLib: Exploring the Kinase Inhibitor Space Using Subpocket-Focused Fragmentation and Recombination. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 6081-6094.	5.4	15
206	Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilinoquinoline Inhibitors. <i>ChemMedChem</i> , 2020, 15, 1200-1215.	3.2	9
207	Discovery of new potential CDK2/VEGFR2 type II inhibitors by fragmentation and virtual screening of natural products. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 39, 1-15.	3.5	5
208	Using SMOTE to Deal with Class-Imbalance Problem in Bioactivity Data to Predict mTOR Inhibitors. <i>SN Computer Science</i> , 2020, 1, 1.	3.6	8
209	Catalytic Subunit of PKA as a Prototype of the Eukaryotic Protein Kinase Family. <i>Biochemistry (Moscow)</i> , 2020, 85, 409-424.	1.5	8
210	Assessing the information content of structural and protein-ligand interaction representations for the classification of kinase inhibitor binding modes via machine learning and active learning. <i>Journal of Cheminformatics</i> , 2020, 12, 36.	6.1	14
211	Potent dual EGFR/Her4 tyrosine kinase inhibitors containing novel (1,2-dithiolan-4-yl)acetamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127288.	2.2	5
212	MET-dependent solid tumours – molecular diagnosis and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 569-587.	27.6	165
213	Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. <i>Cancer Cell</i> , 2020, 38, 129-143.e7.	16.8	57
214	Tyrosine kinase inhibitors modulate dendritic cell activity via confining c-Kit signaling and tryptophan metabolism. <i>International Immunopharmacology</i> , 2020, 82, 106357.	3.8	11
215	Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. <i>Topics in Medicinal Chemistry</i> , 2020, , 155-201.	0.8	0
216	Mining Public Domain Data to Develop Selective DYRK1A Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1620-1626.	2.8	10
217	Conformational selection vs. induced fit: insights into the binding mechanisms of p38 MAP Kinase inhibitors. <i>Chemical Communications</i> , 2020, 56, 8818-8821.	4.1	6
218	Inter-lobe Motions Allosterically Regulate the Structure and Function of EGFR Kinase. <i>Journal of Molecular Biology</i> , 2020, 432, 4561-4575.	4.2	5
219	Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 229-249.	2.4	27
220	Emerging roles of the $\beta 2$ loop in protein kinase structure, function, evolution, and disease. <i>IUBMB Life</i> , 2020, 72, 1189-1202.	3.4	22

#	ARTICLE	IF	CITATIONS
221	Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type. <i>Molecules</i> , 2020, 25, 938.	3.8	7
222	Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles. <i>Molecules</i> , 2020, 25, 770.	3.8	31
223	The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. <i>Pharmacological Research</i> , 2020, 155, 104725.	7.1	21
224	In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. <i>Frontiers in Chemistry</i> , 2019, 7, 873.	3.6	71
225	The role of JAK/STAT signaling pathway and its inhibitors in diseases. <i>International Immunopharmacology</i> , 2020, 80, 106210.	3.8	424
226	Allosterische Kinaseinhibitoren – Erwartungen und Chancen. <i>Angewandte Chemie</i> , 2020, 132, 13868-13881.	2.0	2
227	Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115525.	3.0	28
228	Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1234-1245.	6.1	15
229	Modulation of endoplasmic reticulum stress response in gut-origin encephalopathy: Impact of vascular endothelial growth factor receptor-2 manipulation. <i>Life Sciences</i> , 2020, 252, 117654.	4.3	11
230	In Search of Outliers. Mining for Protein Kinase Inhibitors Based on Their Anti-Proliferative NCI-60 Cell Lines Profile. <i>Molecules</i> , 2020, 25, 1766.	3.8	2
231	Insights into features and lead optimization of novel type 1½ inhibitors of p38 mitogen-activated protein kinase using QSAR, quantum mechanics, bioisostere replacement and ADMET studies. <i>Results in Chemistry</i> , 2020, 2, 100044.	2.0	6
232	<sc>Câ€œH</sc>â€œO hydrogen bonds in kinaseâ€œinhibitor interfaces. <i>IUBMB Life</i> , 2020, 72, 1233-1242.	3.4	7
233	Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use. <i>Journal of Virology</i> , 2020, 94, .	3.4	12
234	Discovery and Structureâ€œActivity Relationship Study of (<i>Z</i>)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4880-4895.	6.4	17
235	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. <i>Cancers</i> , 2020, 12, 927.	3.7	6
236	Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2167.	4.1	8
237	Rational drug repurposing for cancer by inclusion of the unbiased molecular dynamics simulation in the structure-based virtual screening approach: Challenges and breakthroughs. <i>Seminars in Cancer Biology</i> , 2021, 68, 249-257.	9.6	20
238	FCXâ€œ146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the secondâ€œgeneration arylidene indanone scaffold. <i>Biotechnology and Applied Biochemistry</i> , 2021, 68, 82-91.	3.1	17

#	ARTICLE	IF	CITATIONS
239	The MEK/ERK Network as a Therapeutic Target in Human Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 361-374.	3.4	95
240	RIPK protein kinase family: Atypical lives of typical kinases. <i>Seminars in Cell and Developmental Biology</i> , 2021, 109, 96-105.	5.0	44
241	KLIFS: an overhaul after the first 5 years of supporting kinase research. <i>Nucleic Acids Research</i> , 2021, 49, D562-D569.	14.5	74
242	Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. <i>Biochemical Pharmacology</i> , 2021, 183, 114348.	4.4	8
243	Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo. <i>Biomedicine and Pharmacotherapy</i> , 2021, 134, 111134.	5.6	9
244	Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3 β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and <i>in silico</i> studies. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 271-286.	5.2	52
245	Comparative Efficacy and Safety of Different Regimens of Advanced Gastrointestinal Stromal Tumors After Failure Prior Tyrosine Kinase Inhibitors: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2021, 38, 399-412.	2.9	3
246	A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1275, 357-382.	1.6	2
247	Type II Binders Targeting the α GLR-Out Conformation of the Pseudokinase STRAD β . <i>Biochemistry</i> , 2021, 60, 289-302.	2.5	6
248	Current and future treatment options for <i>MET</i> exon 14 skipping alterations in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199297.	3.2	40
249	The mechanism of activation of monomeric B-Raf V600E. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3349-3363.	4.1	38
250	Dual roles of ATP-binding site in protein kinases: Orthosteric inhibition and allosteric regulation. <i>Advances in Protein Chemistry and Structural Biology</i> , 2021, 124, 87-119.	2.3	10
251	Allosteric Modulation. , 2021, , .		0
252	TgIF2K-B Is an eIF2 β Kinase in <i>Toxoplasma gondii</i> That Responds to Oxidative Stress and Optimizes Pathogenicity. <i>MBio</i> , 2021, 12, .	4.1	23
253	Design and Discovery of Kinase Inhibitors Using Docking Studies. , 2021, , 337-365.		0
254	Nanomedicine of tyrosine kinase inhibitors. <i>Theranostics</i> , 2021, 11, 1546-1567.	10.0	19
255	Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 228-235.	2.8	3
256	Design, synthesis and <i>in silico</i> insights of new 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities. <i>Bioorganic Chemistry</i> , 2021, 107, 104569.	4.1	18

#	ARTICLE	IF	CITATIONS
257	Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). <i>Molecules</i> , 2021, 26, 1076.	3.8	39
259	Halogen Atoms in the Proteinâ€“Ligand System. Structural and Thermodynamic Studies of the Binding of Bromobenzotriazoles by the Catalytic Subunit of Human Protein Kinase CK2. <i>Journal of Physical Chemistry B</i> , 2021, 125, 2491-2503.	2.6	13
260	Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). <i>Pharmacological Research</i> , 2021, 165, 105422.	7.1	46
261	Generating Selective Leads for Mer Kinase Inhibitorsâ€“Example of a Comprehensive Lead-Generation Strategy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3165-3184.	6.4	11
263	Probes for Photoaffinity Labelling of Kinases. <i>ChemBioChem</i> , 2021, 22, 2206-2218.	2.6	4
264	Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1265-1282.	6.4	7
265	Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. <i>Pharmacological Research</i> , 2021, 165, 105463.	7.1	242
267	Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells. <i>Bioorganic Chemistry</i> , 2021, 109, 104752.	4.1	17
268	Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 38, 127862.	2.2	17
270	Recent advances in development of hetero-bivalent kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 216, 113318.	5.5	15
272	Recent progress in small-molecule inhibitors for critical therapeutic targets of necroptosis. <i>Future Medicinal Chemistry</i> , 2021, 13, 817-837.	2.3	4
273	Classical MD and metadynamics simulations on back-pocket binders of CDK2 and VEGFR2: a guidepost to design novel small-molecule dual inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9030-9041.	3.5	1
274	Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. <i>Frontiers in Oncology</i> , 2021, 11, 643382.	2.8	21
275	Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer. <i>Cells</i> , 2021, 10, 1154.	4.1	21
276	Approach in Improving Potency and Selectivity of Kinase Inhibitors: Allosteric Kinase Inhibitors. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 991-1003.	2.4	4
277	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 201.	17.1	607
278	Modulation of Src Kinase Activity by Selective Substrate Recognition with Pseudopeptidic Cages. <i>Chemistry - A European Journal</i> , 2021, 27, 9542-9549.	3.3	5
279	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. <i>Circulation Research</i> , 2021, 128, 1973-1987.	4.5	10

#	ARTICLE	IF	CITATIONS
280	Electronic and structural study of T315I mutated form in DFG-out conformation of BCR-ABL inhibitors. Journal of Biomolecular Structure and Dynamics, 2021, , 1-15.	3.5	4
281	Chemical and Biophysical Approaches to Allosteric Modulation. European Journal of Organic Chemistry, 2021, 2021, 4245-4259.	2.4	2
282	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacological Research, 2021, 168, 105579.	7.1	39
283	Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. ELife, 2021, 10, .	6.0	12
284	Discovery of a cooperative mode of inhibiting RIPK1 kinase. Cell Discovery, 2021, 7, 41.	6.7	14
286	Progress in the therapeutic inhibition of Cdc42 signalling. Biochemical Society Transactions, 2021, 49, 1443-1456.	3.4	25
287	Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncology, The, 2021, 22, 946-958.	10.7	100
288	Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 43, 128058.	2.2	8
289	Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma. Bioorganic Chemistry, 2021, 112, 104985.	4.1	13
290	Impact of Selected Small-Molecule Kinase Inhibitors on Lipid Membranes. Pharmaceuticals, 2021, 14, 746.	3.8	6
291	From structure to Å tiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease. Biochemical Journal, 2021, 478, 2945-2951.	3.7	3
292	Molecular Plasticity of Crystalline CK2±â€² Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity. Journal of Medicinal Chemistry, 2022, 65, 1302-1312.	6.4	13
293	Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes. Pharmacological Research, 2021, 169, 105660.	7.1	16
294	The Many Faces of JAKs and STATs Within the COVID-19 Storm. Frontiers in Immunology, 2021, 12, 690477.	4.8	18
295	Molecular-Genetic Basis of Gastrointestinal Stromal Tumor Personalized Therapy by Receptor Tyrosine Kinase Inhibitors (A Review). Pharmaceutical Chemistry Journal, 2021, 55, 315.	0.8	2
296	Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment. Molecules, 2021, 26, 4462.	3.8	22
297	Trends in kinase drug discovery: targets, indications and inhibitor design. Nature Reviews Drug Discovery, 2021, 20, 839-861.	46.4	340
298	CAR T-Cell Therapy in Hematological Malignancies. International Journal of Molecular Sciences, 2021, 22, 8996.	4.1	73

#	ARTICLE	IF	CITATIONS
300	Correlation Analysis of Target Selectivity and Side Effects of FDA-Approved Kinase Inhibitors**. ChemistrySelect, 2021, 6, 7799-7814.	1.5	3
301	OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. Future Oncology, 2021, 17, 4249-4261.	2.4	2
302	Structural Biology of <scp>LRRK2</scp> and its Interaction with Microtubules. Movement Disorders, 2021, 36, 2494-2504.	3.9	10
303	Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. Journal of Medicinal Chemistry, 2021, 64, 11747-11773.	6.4	13
304	Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anti-Cancer Drugs, 2022, 33, e813-e817.	1.4	4
305	Structural and molecular bases to IRE1 activity modulation. Biochemical Journal, 2021, 478, 2953-2975.	3.7	7
306	Using the Structural Kinome to Systematize Kinase Drug Discovery. Biochemistry, 0, , .	1.2	1
307	Chemical Probes for Understudied Kinases: Challenges and Opportunities. Journal of Medicinal Chemistry, 2022, 65, 1132-1170.	6.4	15
308	Update on the Development of MNK Inhibitors as Therapeutic Agents. Journal of Medicinal Chemistry, 2022, 65, 983-1007.	6.4	20
309	Î ² -Caryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models. International Journal of Molecular Sciences, 2021, 22, 10550.	4.1	13
310	In Silico Identification and Evaluation of Natural Products as Potential Tumor Necrosis Factor Function Inhibitors Using Advanced Enalos Asclepios KNIME Nodes. International Journal of Molecular Sciences, 2021, 22, 10220.	4.1	10
311	Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer. Cancers, 2021, 13, 4486.	3.7	3
312	Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer. International Journal of Molecular Sciences, 2021, 22, 9953.	4.1	29
313	An Efficient Second-Generation Manufacturing Process for the pan-RAF Inhibitor Belvarafenib. Organic Process Research and Development, 2021, 25, 2338-2350.	2.7	6
314	Multiscale computational study of ligand binding pathways: Case of p38 MAP kinase and its inhibitors. Biophysical Journal, 2021, 120, 3881-3892.	0.5	13
315	Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorganic and Medicinal Chemistry, 2021, 46, 116384.	3.0	21
316	Optimization of an Imidazo[1,2- <i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> Efficacy. Journal of Medicinal Chemistry, 2021, 64, 13524-13539.	6.4	13
317	Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Review of Clinical Pharmacology, 2021, 14, 1233-1252.	3.1	14

#	ARTICLE	IF	CITATIONS
318	Intrinsic relative preference profile of pan-kinase inhibitor drug staurosporine towards the clinically occurring gatekeeper mutations in Protein Tyrosine Kinases. Computational Biology and Chemistry, 2021, 94, 107562.	2.3	2
319	Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)â†. ESMO Open, 2021, 6, 100250.	4.5	27
320	Novel diarylamides and diarylureas with N-substitution dependent activity against medulloblastoma. European Journal of Medicinal Chemistry, 2021, 225, 113751.	5.5	3
321	Molecular dynamics study of enhanced autophosphorylation by S904F mutation of the RET kinase domain. Journal of Structural Biology, 2021, 213, 107799.	2.8	2
322	Extended many-item similarity indices for sets of nucleotide and protein sequences. Computational and Structural Biotechnology Journal, 2021, 19, 3628-3639.	4.1	10
323	Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia. Cancers, 2021, 13, 184.	3.7	40
324	Identification of novel compounds that inhibit SnRK2 kinase activity by high-throughput screening. Biochemical and Biophysical Research Communications, 2021, 537, 57-63.	2.1	6
325	Design, synthesis, and molecular docking of novel 2â€rylbenzothiazole multiangiokinase inhibitors targeting breast cancer. Archiv Der Pharmazie, 2020, 353, e1900340.	4.1	24
326	Imatinib: Basic Results. , 2017, , 11-31.		1
327	Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors. Advances in Experimental Medicine and Biology, 2019, 1163, 253-278.	1.6	18
328	Interrogating Regulatory Mechanisms in Signaling Proteins by Allosteric Inhibitors and Activators: A Dynamic View Through the Lens of Residue Interaction Networks. Advances in Experimental Medicine and Biology, 2019, 1163, 187-223.	1.6	17
329	A ligand-centric approach to identify potential drugs for repurposing. , 2020, , 15-54.		2
330	A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein. Communications Biology, 2020, 3, 18.	4.4	12
331	The structure of human GCN2 reveals a parallel, back-to-back kinase dimer with a plastic DFG activation loop motif. Biochemical Journal, 2020, 477, 275-284.	3.7	13
332	Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish forâ€ . Biochemical Society Transactions, 2020, 48, 1859-1875.	3.4	22
334	Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways. PLoS ONE, 2016, 11, e0166583.	2.5	28
335	Pockets as structural descriptors of EGFR kinase conformations. PLoS ONE, 2017, 12, e0189147.	2.5	15
336	Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions. Oncotarget, 2017, 8, 5540-5565.	1.8	14

#	ARTICLE	IF	CITATIONS
337	Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. <i>Oncotarget</i> , 2018, 9, 13796-13806.	1.8	43
338	Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors. <i>Current Enzyme Inhibition</i> , 2020, 16, 90-105.	0.4	2
339	The Interactions of Nintedanib and Oral Anticoagulantsâ€™ Molecular Mechanisms and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 282.	4.1	18
340	Synthesis and biological evaluation of novel amino-substituted derivatives of pyrido[2,3-d]pyrimidine as inhibitors of protein kinase CK2. <i>Biopolymers and Cell</i> , 2017, 33, 367-378.	0.4	4
341	Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. <i>ELife</i> , 2020, 9, .	6.0	25
342	Brutonâ€™s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. <i>Drugs</i> , 2021, 81, 1605-1626.	10.9	29
343	Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations. <i>Pharmaceutics</i> , 2021, 13, 1604.	4.5	4
344	Small Molecule Kinase Inhibitor Drugs (1995â€“2021): Medical Indication, Pharmacology, and Synthesis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1047-1131.	6.4	114
345	Homology Modelling, Docking-based Virtual Screening, ADME Properties, and Molecular Dynamics Simulation for Identification of Probable Type II Inhibitors of AXL Kinase. <i>Letters in Drug Design and Discovery</i> , 2022, 19, 214-241.	0.7	1
346	Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14477-14497.	6.4	17
347	Royaume du Maroc. <i>PrÃ©sence Africaine</i> , 1962, NÂ° XLII, 147-151.	0.0	3
348	Novel FRET-Based Src Biosensor Reveals Mechanisms of Src Activation and Its Dynamics in Focal Adhesions. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
354	Rational Design of Potential Bcr-Abl Tyrosine Kinase Inhibitors by the Methods of Molecular Modeling. <i>Mathematical Biology and Bioinformatics</i> , 2020, 15, 396-415.	0.6	1
355	Novel Peptide-Based Inhibitors of Protein Kinases. , 2020, , 169-206.		1
356	Chemical Probes for Kinases. <i>Chemical Biology</i> , 2020, , 182-213.	0.2	0
358	How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 53, 116534.	3.0	7
359	Tumor-Targeting Agents. , 2022, , 217-236.		3
360	From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1481-1504.	6.4	16

#	ARTICLE	IF	CITATIONS
361	Synthesis, In Vitro and In Silico Anticancer Activity of New 4-Methylbenzamide Derivatives Containing 2,6-Substituted Purines as Potential Protein Kinases Inhibitors. International Journal of Molecular Sciences, 2021, 22, 12738.	4.1	5
362	Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy. Biological and Pharmaceutical Bulletin, 2021, 44, 1872-1877.	1.4	2
363	Design, synthesis, anticancer, and docking of some Sâ€•and/or Nâ€•heterocyclic derivatives as VEGFRâ€•2 inhibitors. Archiv Der Pharmazie, 2021, , e2100237.	4.1	6
364	Potent and Selective RIPK1 Inhibitors Targeting Dualâ€•Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis. Angewandte Chemie, 2022, 134, e202114922.	2.0	0
365	Potent and Selective RIPK1 Inhibitors Targeting Dualâ€•Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis. Angewandte Chemie - International Edition, 2022, 61, .	13.8	17
366	Lead optimization, pharmacophore development and scaffold design of protein kinase CK2 inhibitors as potential COVID-19 therapeutics. Journal of Biomolecular Structure and Dynamics, 2023, 41, 1811-1827.	3.5	5
367	Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development. Molecules, 2022, 27, 347.	3.8	6
368	NTRK point mutations and their functional consequences. Cancer Genetics, 2022, 262-263, 5-15.	0.4	6
369	Exploring the Conformational Landscape and Stability of Aurora A Using Ion-Mobility Mass Spectrometry and Molecular Modeling. Journal of the American Society for Mass Spectrometry, 2022, 33, 420-435.	2.8	3
370	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules, 2022, 27, 819.	3.8	32
371	Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Critical Reviews in Oncology/Hematology, 2022, 171, 103580.	4.4	21
372	Kinase Inhibitors Involved in the Regulation of Autophagy: Molecular Concepts and Clinical Implications. Current Medicinal Chemistry, 2023, 30, 1502-1528.	2.4	3
373	Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacological Research, 2022, 175, 106037.	7.1	136
374	Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia. OncoTargets and Therapy, 2022, Volume 15, 103-116.	2.0	6
375	Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Bioorganic and Medicinal Chemistry Letters, 2022, 58, 128529.	2.2	22
376	Putative dual inhibitors of mTOR and RET kinase from natural products: Pharmacophore-based hierarchical virtual screening. Journal of Molecular Liquids, 2022, 350, 118562.	4.9	5
377	Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase Î³ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode. Journal of Medicinal Chemistry, 2022, 65, 3359-3370.	6.4	14
378	Tracking protein domain movements by EPR distance determination and multilateration. Methods in Enzymology, 2022, 666, 121-144.	1.0	2

#	ARTICLE	IF	CITATIONS
380	Effective Reaction-Based <i>De Novo</i> Strategy for Kinase Targets: A Case Study on MERTK Inhibitors. Journal of Chemical Information and Modeling, 2022, 62, 1654-1668.	5.4	3
381	Emerging Novel Combined CAR-T Cell Therapies. Cancers, 2022, 14, 1403.	3.7	9
382	Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution. International Journal of Molecular Sciences, 2022, 23, 3830.	4.1	2
383	Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. International Journal of Molecular Sciences, 2022, 23, 2815.	4.1	15
384	Principles of Kinase Allosteric Inhibition and Pocket Validation. Journal of Medicinal Chemistry, 2022, 65, 5288-5299.	6.4	19
386	A recent update on small-molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry-based proteomic analysis. FEBS Journal, 2023, 290, 2845-2864.	4.7	21
387	Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?. Current Treatment Options in Oncology, 2022, 23, 749-761.	3.0	5
388	Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188725.	7.4	12
389	Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Pharmacological Research, 2022, 178, 106156.	7.1	30
390	Identification of a novel anticancer mechanism of Paeoniae Radix extracts based on systematic transcriptome analysis. Biomedicine and Pharmacotherapy, 2022, 148, 112748.	5.6	9
391	Design and development of photoswitchable DFG-Out RET kinase inhibitors. European Journal of Medicinal Chemistry, 2022, 234, 114226.	5.5	7
392	Met inhibitors in the treatment of lung cancer: the evidence to date. Expert Opinion on Pharmacotherapy, 2022, , .	1.8	0
393	TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults. Cancer Genetics, 2022, 264-265, 33-39.	0.4	16
394	Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors. European Journal of Medicinal Chemistry, 2022, 236, 114345.	5.5	10
395	Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics, 2022, 21, 336-346.	4.1	20
396	Active Site Sequence Representations of Human Kinases Outperform Full Sequence Representations for Affinity Prediction and Inhibitor Generation: 3D Effects in a 1D Model. Journal of Chemical Information and Modeling, 2022, 62, 240-257.	5.4	14
397	Generation of inhibitory peptides for μ from a kinase-focused phage library of helix-loop-helix peptides. Peptide Science, 2022, 114, .	1.8	0
398	MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review. Journal of Personalized Medicine, 2021, 11, 1370.	2.5	8

#	ARTICLE	IF	CITATIONS
399	Introductory Chapter: Protein Kinases as Promising Targets for Drug Design against Cancer. Biochemistry, 0, , .	1.2	5
400	Targeting mutations in cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	56
401	Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 6070-6087.	6.4	9
404	Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and <i>in silico</i> insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1227-1240.	5.2	15
405	Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1257-1277.	5.2	2
406	Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking. Bioorganic Chemistry, 2022, 125, 105861.	4.1	11
407	Drug discovery for cancer therapy with special reference to inhibitors of protein kinase pathway. , 2022, , 71-96.		2
408	Recent advances in the therapeutic development of ERK inhibitors. , 2022, , 129-178.		0
409	Protein kinase inhibitors and cancer targeted therapy. , 2022, , 23-70.		0
410	Nanotechnology-based targeted delivery systems for protein kinase inhibitors in Cancer therapy. , 2022, , 747-779.		0
411	Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy. Cancers, 2022, 14, 2488.	3.7	7
412	Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib. Computational and Structural Biotechnology Journal, 2022, 20, 2574-2586.	4.1	5
413	The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug. Journal of Medicinal Chemistry, 2022, 65, 7581-7594.	6.4	11
414	Expedient Access to Type II Kinase Inhibitor Chemotypes by Microwave-Assisted Suzuki Coupling. , 2022, 1, 64-72.		2
415	Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. Cancer Letters, 2022, 547, 215775.	7.2	7
416	Identification of non-ATP-competitive \pm -carboline inhibitors of the anaplastic lymphoma kinase. European Journal of Medicinal Chemistry, 2022, 238, 114488.	5.5	3
417	Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors. Bioorganic Chemistry, 2022, 126, 105883.	4.1	13
418	Exploring kinase family inhibitors and their moiety preferences using deep SHapley additive exPlanations. BMC Bioinformatics, 2022, 23, .	2.6	2

#	ARTICLE	IF	CITATIONS
419	Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2022, 65, 8065-8090.	6.4	15
420	Maximizing the integration of virtual and experimental screening in hit discovery. Expert Opinion on Drug Discovery, 0, , 1-12.	5.0	0
421	In vitro Anti-Hantavirus Activity of Protein Kinase Inhibitor 8G1 Targeting AKT/mTOR/eIF4E Signaling Pathway. Frontiers in Microbiology, 0, 13, .	3.5	0
422	An Appraisal on Synthetic and Medicinal Aspects of Fused Pyrimidines as Anti Neoplastic Agents.. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, .	1.7	5
423	DOCKSTRING: Easy Molecular Docking Yields Better Benchmarks for Ligand Design. Journal of Chemical Information and Modeling, 2022, 62, 3486-3502.	5.4	25
424	Targeting Streptomyces-Derived Streptenol Derivatives against Gynecological Cancer Target PIK3CA: An In Silico Approach. BioMed Research International, 2022, 2022, 1-15.	1.9	2
425	Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. Journal of Biological Chemistry, 2022, 298, 102247.	3.4	31
426	Emerging strategies to overcome resistance to third-generation EGFR inhibitors. Journal of Hematology and Oncology, 2022, 15, .	17.0	48
427	Recent advances in targeting protein kinases and pseudokinases in cancer biology. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	4
428	Precision Medicine in Therapy of Non-solid Cancer. Handbook of Experimental Pharmacology, 2022, , .	1.8	0
429	Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer. Medicinal Chemistry Research, 2022, 31, 1401-1413.	2.4	1
430	Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacological Research, 2022, 183, 106362.	7.1	33
431	Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors. European Journal of Medicinal Chemistry, 2022, 243, 114782.	5.5	3
432	Electronic and Structural Insights of BCR-ABL Inhibitors Under LMC Treatment Perspective. Engineering Materials, 2022, , 389-404.	0.6	0
433	Therapeutic peptides targeting protein kinase: progress, challenges, and future directions, featuring cancer and cardiovascular disease. , 2022, , 333-356.		0
434	BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity. Experimental and Molecular Medicine, 2022, 54, 1450-1460.	7.7	4
435	Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	51
436	A Perspective Study on the RTK, PI3K, Bâ€Raf, CDK and the Multiâ€Protein Targeting in Medicinal Chemistry. Chemistry and Biodiversity, 2022, 19, .	2.1	2

#	ARTICLE	IF	CITATIONS
437	Potential use of lapatinib in the treatment of head and neck squamous cell carcinoma (Review). World Academy of Sciences Journal, 2022, 4, .	0.6	0
438	Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. Medicinal Chemistry Research, 2022, 31, 1647-1662.	2.4	9
439	The development of small-molecule inhibitors targeting HPK1. European Journal of Medicinal Chemistry, 2022, 244, 114819.	5.5	12
440	Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. , 2022, , 251-267.		0
442	<scp>kinCSM</scp>: Using graphâ€based signatures to predict small molecule <scp>CDK2</scp> inhibitors. Protein Science, 2022, 31, .	7.6	5
443	Rational Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Based Antiproliferative Agents in MCF-7 Cancer Cells. Pharmaceuticals, 2022, 15, 1245.	3.8	4
444	Molecular targeted therapy for anticancer treatment. Experimental and Molecular Medicine, 2022, 54, 1670-1694.	7.7	57
445	Identification of defactinib derivatives targeting focal adhesion kinase using ensemble docking, molecular dynamics simulations and binding free energy calculations. Journal of Biomolecular Structure and Dynamics, 2023, 41, 8654-8670.	3.5	2
446	Targeting lipidâ€protein interaction to treat Syk-mediated acute myeloid leukemia. Nature Chemical Biology, 2023, 19, 239-250.	8.0	10
447	Actives-Based Receptor Selection Strongly Increases the Success Rate in Structure-Based Drug Design and Leads to Identification of 22 Potent Cancer Inhibitors. Journal of Chemical Information and Modeling, 2022, 62, 5675-5687.	5.4	3
448	Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. European Journal of Cancer, 2023, 179, 124-135.	2.8	11
449	Novel 2â€oxoâ€2â€phenylethoxy and benzyloxy diaryl urea hybrids as VEGFRâ€2 inhibitors: Design, synthesis, and anticancer evaluation. Archiv Der Pharmazie, 2023, 356, .	4.1	2
450	Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacological Research, 2023, 187, 106552.	7.1	99
451	Emerging approaches to CDK inhibitor development, a structural perspective. RSC Chemical Biology, 2023, 4, 146-164.	4.1	4
452	N1-(3-(Trifluoromethyl)Phenyl) Isophthalamide Derivatives as Promising Inhibitors of Vascular Endothelial Growth Factor Receptor: Pharmacophore-Based Design, Docking, and MM-PBSA/MM-GBSA Binding Energy Estimation. , 0, , .		0
453	Structural Insights into the Interactions of Belumosudil with Rho-Associated Coiled-Coil Containing Protein Kinases 1 and 2 Based on Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculations. Journal of Computational Biophysics and Chemistry, 2023, 22, 401-422.	1.7	3
454	Molecular dissection of Janus kinases as drug targets for inflammatory diseases. Frontiers in Immunology, 0, 13, .	4.8	3
455	Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy. Pharmaceuticals, 2022, 14, 2706.	4.5	4

#	ARTICLE	IF	CITATIONS
457	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
458	MECHANISM OF ACTION, SYNTHESIS, PROPERTIES AND ANALYTICAL METHODS OF CABOZANTINIB. <i>International Journal of Applied Pharmaceutics</i> , 0, , 57-65.	0.3	0
459	Molecular dynamics simulation study on the inhibitory mechanism of RIPK1 by 4,5-dihydropyrazole derivatives. <i>Molecular Physics</i> , 2023, 121, .	1.7	1
462	Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. <i>Molecules</i> , 2023, 28, 943.	3.8	3
463	New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and <i>in silico</i> study. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2023, 38, .	5.2	9
464	Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
465	Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance. <i>Molecular Systems Biology</i> , 2023, 19, .	7.2	14
466	Structural mechanism of a drug-binding process involving a large conformational change of the protein target. <i>Nature Communications</i> , 2023, 14, .	12.8	20
467	Activation of Gcn2 by small molecules designed to be inhibitors. <i>Journal of Biological Chemistry</i> , 2023, 299, 104595.	3.4	8
468	Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3073-3087.	6.4	3
469	KinFams: De-Novo Classification of Protein Kinases Using CATH Functional Units. <i>Biomolecules</i> , 2023, 13, 277.	4.0	3
470	Utilization of kinase inhibitors as novel therapeutic drug targets: A review. <i>Oncology Research</i> , 2022, 30, 221-230.	1.5	4
471	Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. <i>Pharmacological Research</i> , 2023, 189, 106642.	7.1	21
472	Allosteric regulation and inhibition of protein kinases. <i>Biochemical Society Transactions</i> , 2023, 51, 373-385.	3.4	6
473	Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. <i>Pharmaceutics</i> , 2023, 15, 664.	4.5	2
474	New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization. <i>Molecular Diversity</i> , 0, , .	3.9	1
475	Strategy toward Kinase-Selective Drug Discovery. <i>Journal of Chemical Theory and Computation</i> , 2023, 19, 1615-1628.	5.3	7
476	Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition. <i>Drug Research</i> , 2023, 73, 189-199.	1.7	4

#	ARTICLE	IF	CITATIONS
477	Natural Products in Precision Oncology: Plant-Based Small Molecule Inhibitors of Protein Kinases for Cancer Chemoprevention. <i>Nutrients</i> , 2023, 15, 1192.	4.1	4
478	Targeted Therapies: A Molecular Overview. <i>Åœronkoloji BÃ¼lteni</i> , 2023, 22, 1-14.	0.1	0
479	Inhibition of protein kinase C delta leads to cellular senescence to induce anti-tumor effects in colorectal cancer. <i>Cancer Science</i> , 2023, 114, 2471-2484.	3.9	1
480	Small molecules targeting endocytic uptake and recycling pathways. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	0
481	Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. <i>Journal of Biological Chemistry</i> , 2023, 299, 104634.	3.4	8
482	Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present). <i>Expert Opinion on Therapeutic Patents</i> , 2023, 33, 101-124.	5.0	3
483	2-Phenylquinazolin-4(3H)-one scaffold as newly designed, synthesized VEGFR-2 allosteric inhibitors with potent cytotoxicity through apoptosis. <i>Archiv Der Pharmazie</i> , 2023, 356, .	4.1	2
484	Analysis of the ERK Pathway Cysteinome for Targeted Covalent Inhibition of RAF and MEK Kinases. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 2483-2494.	5.4	3
485	Structure-based virtual screening and molecular dynamics simulations for detecting novel candidates for allosteric inhibition of EGFR T790M. <i>Journal of Biomolecular Structure and Dynamics</i> , 2024, 42, 571-597.	3.5	1
486	Capturing Differences in the Regulation of LRRK2 Dynamics and Conformational States by Small Molecule Kinase Inhibitors. <i>ACS Chemical Biology</i> , 2023, 18, 810-821.	3.4	10
487	Interactions between curcumin and human salt-induced kinase 3 elucidated from computational tools and experimental methods. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
488	Profiling of small-molecule necroptosis inhibitors based on the subpockets of kinase-ligand interactions. <i>Medicinal Research Reviews</i> , 2023, 43, 1974-2024.	10.5	4
489	Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. <i>MedComm</i> , 2023, 4, .	7.2	17
491	Photoswitchable Inhibitors to Optically Control Specific Kinase Activity. <i>ACS Chemical Biology</i> , 2023, 18, 1378-1387.	3.4	2
492	Novel VEGFR-2 inhibitors as antiangiogenic and apoptotic agents via paracrine and autocrine cascades: Design, synthesis, and biological evaluation. <i>Bioorganic Chemistry</i> , 2023, 139, 106678.	4.1	0
493	Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management. , 2023, , 1-19.		0
494	A demand-offer critical analysis of current drug development. Phase I drugs Vs TCGA sequencing data. <i>European Journal of Cancer</i> , 2023, , 112958.	2.8	0
495	Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 8782-8807.	6.4	4

#	ARTICLE	IF	CITATIONS
496	Identification of the active compounds in the Yi-Fei-San-Jie formula using a comprehensive strategy based on cell extraction/UPLC-MS/MS, network pharmacology, and molecular biology techniques. <i>Phytomedicine</i> , 2023, 115, 154843.	5.3	0
497	Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	3
498	Discovery of highly potent and selective VEGFR2 kinase inhibitors for the treatment of rheumatoid arthritis. <i>European Journal of Medicinal Chemistry</i> , 2023, 257, 115456.	5.5	2
499	Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi-active components combination. <i>Medicinal Research Reviews</i> , 2023, 43, 1778-1808.	10.5	9
500	Analysis of the binding pattern of NIK inhibitors by computational simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2024, 42, 3318-3331.	3.5	1
501	Identification of IL-2 inducible tyrosine kinase inhibitors by quantum mechanics and ligand based virtual screening approaches. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-11.	3.5	0
502	Quantitatively Accounting for Protein Reorganization in Computer-Aided Drug Design. <i>Journal of Chemical Theory and Computation</i> , 2023, 19, 3080-3090.	5.3	4
503	Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies. <i>European Journal of Medicinal Chemistry</i> , 2023, 259, 115626.	5.5	7
504	The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies. <i>Molecules</i> , 2023, 28, 5359.	3.8	6
505	Development of Kinase-Centric Drugs: A Computational Perspective. <i>ChemMedChem</i> , 2023, 18, .	3.2	2
506	Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States. <i>Pharmacological Research</i> , 2023, 194, 106847.	7.1	0
507	MET-Targeting Anticancer Drugs-De Novo Design and Identification by Drug Repurposing. , 2023, 2, 591-623.		2
508	DELs enable the development of BRET probes for target engagement studies in cells. <i>Cell Chemical Biology</i> , 2023, 30, 987-998.e24.	5.2	2
509	HYDROGEN/DEUTERIUM EXCHANGE-MASS SPECTROMETRY IN MEDICINAL CHEMISTRY. <i>Medicinal Chemistry Reviews</i> , 0, , 465-487.	0.1	0
510	Synthesis, structure characterization, DFT calculations, and computational anticancer activity investigations of 1-phenyl ethanol derivatives. <i>Journal of Molecular Structure</i> , 2023, 1294, 136323.	3.6	4
511	A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of <sc>SN1011</sc> in healthy subjects. <i>Clinical and Translational Science</i> , 2023, 16, 1982-1996.	3.1	0
512	Progress on the Pharmacological Targeting of Janus Pseudokinases. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 10959-10990.	6.4	1
513	Role of the Residue Q1919 in Increasing Kinase Activity of G2019S LRRK2 Kinase: A Computational Study. <i>ChemPhysChem</i> , 2023, 24, .	2.1	1

#	ARTICLE	IF	CITATIONS
514	RET-Altered Cancersâ€”A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity. Cancers, 2023, 15, 4146.	3.7	1
515	Novel azole-urea hybrids as VEGFR-2 inhibitors: Synthesis, in vitro antiproliferative evaluation and in silico studies. Journal of Molecular Structure, 2023, 1294, 136448.	3.6	0
516	How many kinases are druggable? A review of our current understanding. Biochemical Journal, 2023, 480, 1331-1363.	3.7	1
517	Recent advances in targeting the â€œundruggableâ€•proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	11
518	A Combination of Conformation-Specific RAF Inhibitors Overcome Drug Resistance Brought about by RAF Overexpression. Biomolecules, 2023, 13, 1212.	4.0	1
519	Novel 7-Deazapurine Incorporating Isatin Hybrid Compounds as Protein Kinase Inhibitors: Design, Synthesis, In Silico Studies, and Antiproliferative Evaluation. Molecules, 2023, 28, 5869.	3.8	3
520	Investigating the conformational landscape of AlphaFold2-predicted protein kinase structures. Bioinformatics Advances, 2023, 3, .	2.4	2
521	Identification and validation of a small molecule targeting ROR1 for the treatment of triple negative breast cancer. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	0
522	Vepafestininib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nature Cancer, 2023, 4, 1345-1361.	13.2	3
523	2-Aminopyrimidine. , 2023, , 391-404.		0
525	Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases. Frontiers in Pharmacology, 0, 14, .	3.5	3
526	Synthesis of novel pyrido[2,3-d]pyrimidine-thiazolidine-1,2,3-triazoles: Potent EGFR targeting anticancer agents. Journal of Molecular Structure, 2023, 1294, 136451.	3.6	3
531	The D647N mutation of FGFR1 induces ligand-independent receptor activation. Biochimica Et Biophysica Acta - General Subjects, 2023, 1867, 130470.	2.4	1
532	Affimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibition. Cell Reports, 2023, 42, 113184.	6.4	1
533	Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding. Journal of Biological Chemistry, 2023, 299, 105328.	3.4	0
534	Cytotoxic and Antioxidant Potential of Launaea mucronata Forssk Essential Oil Growing in Northern Saudi Arabia. Molecules, 2023, 28, 7025.	3.8	0
535	Candidate Tracers for Imaging Colony-Stimulating Factor 1 Receptor in Neuroinflammation with Positron Emission Tomography: Issues and Progress. ACS Pharmacology and Translational Science, 0, , .	4.9	0
536	The small-molecule kinase inhibitor ceritinib, unlike imatinib, causes a significant disturbance of lipid membrane integrity: A combined experimental and MD study. Chemistry and Physics of Lipids, 2023, 257, 105351.	3.2	0

#	ARTICLE	IF	CITATIONS
537	Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities. <i>Bioorganic Chemistry</i> , 2024, 142, 106934.	4.1	1
538	Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib. <i>Acta Pharmaceutica Sinica B</i> , 2024, 14, 517-532.	12.0	1
539	Discovery of small molecule degraders for modulating cell cycle. <i>Frontiers of Medicine</i> , 2023, 17, 823-854.	3.4	0
540	Newly synthesized 6-substituted piperazine/phenyl-9-cyclopentyl containing purine nucleobase analogs act as potent anticancer agents and induce apoptosis <i>via</i> inhibiting Src in hepatocellular carcinoma cells. <i>RSC Medicinal Chemistry</i> , 0, , .	3.9	0
541	Accelerating Alchemical Free Energy Prediction Using a Multistate Method: Application to Multiple Kinases. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 7133-7147.	5.4	1
542	New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study. <i>Molecules</i> , 2023, 28, 7455.	3.8	3
543	Samson: “They Did Evil in the Eyes of the Lord” The Powerlessness of an Ineffective Follower. , 2023, , 185-196.		0
544	To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, 2877-2972.	2.1	2
545	Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β -Sheet 6 [C ²⁶] Mutation [L2086F]). <i>Journal of Thoracic Oncology</i> , 2023, , .	1.1	0
546	Molecular and functional insight into focal adhesion kinases: Therapeutic implications for oral malignancies. <i>Drug Discovery Today</i> , 2024, 29, 103852.	6.4	0
547	Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases. <i>Pharmacological Research</i> , 2024, 199, 107036.	7.1	0
548	Design and Self Assembly of Tri-Terpene Peptide Conjugates and Their Interactions with EGFR and EGFR Mutant Receptors: An In Silico and In Vitro Study. <i>International Journal of Peptide Research and Therapeutics</i> , 2024, 30, .	1.9	0
549	An Update on Protein Kinases as Therapeutic Targets”Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17600.	4.1	2
550	Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. <i>Cells</i> , 2024, 13, 47.	4.1	1
551	Discovery of dual rho-associated protein kinase 1 (ROCK1)/apoptosis signal-regulating kinase 1 (ASK1) inhibitors as a novel approach for non-alcoholic steatohepatitis (NASH) treatment. <i>BMC Chemistry</i> , 2024, 18, .	3.8	0
552	Molecular Recognition of Tyrosine-Containing Polypeptides with Pseudopeptidic Cages Unraveled by Fluorescence and NMR Spectroscopies. <i>Bioconjugate Chemistry</i> , 2023, 34, 2345-2357.	3.6	0
553	Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. <i>Pharmacological Research</i> , 2024, 200, 107059.	7.1	2
554	Structure-Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review. <i>ACS Omega</i> , 2024, 9, 4186-4209.	3.5	1

#	ARTICLE	IF	CITATIONS
555	Screening Ultra-Large Encoded Compound Libraries Leads to Novel Proteinâ€“Ligand Interactions and High Selectivity. Journal of Medicinal Chemistry, 2024, 67, 864-884.	6.4	0
556	Targeted Therapeutic Strategies for the Treatment of Cancer. Cancers, 2024, 16, 461.	3.7	1
557	Recent advances in multitarget-directed ligands via in silico drug discovery. Drug Discovery Today, 2024, 29, 103904.	6.4	1
558	Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review. Frontiers in Pharmacology, 0, 15, .	3.5	0
559	Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies. BMC Chemistry, 2024, 18, .	3.8	0
560	Novel <scp>RAF</scp>â€“directed approaches to overcome current clinical limits and block the <scp>RAS</scp>/<scp>RAF</scp> node. Molecular Oncology, 0, , .	4.6	0
561	Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells. European Journal of Medicinal Chemistry, 2024, 268, 116255.	5.5	0
562	Mutant anaplastic lymphoma kinase inhibitor identification by integrated in silico approaches. Molecular Simulation, 2024, 50, 404-419.	2.0	0
563	Structureâ€“Activity Relationship of a Pyrrole Based Series of PfPKG Inhibitors as Anti-Malarials. Journal of Medicinal Chemistry, 2024, 67, 3467-3503.	6.4	0
564	Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors. BMC Chemistry, 2024, 18, .	3.8	0
565	New 2-oxoindole derivatives as multiple PDGFRÎ±/Î³ and VEGFR-2 tyrosine kinase inhibitors. Bioorganic Chemistry, 2024, 145, 107234.	4.1	0
566	Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer. Cancer Letters, 2024, 588, 216780.	7.2	0
567	A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics. International Journal of Biological Macromolecules, 2024, 265, 130913.	7.5	0
568	The structures of salt-inducible kinase 3 in complex with inhibitors reveal determinants for binding and selectivity. Journal of Biological Chemistry, 2024, 300, 107201.	3.4	0
569	Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors. European Journal of Pharmacology, 2024, 970, 176484.	3.5	0
570	Molecular basis for differential recognition of an allosteric inhibitor by receptor tyrosine kinases. Proteins: Structure, Function and Bioinformatics, 0, , .	2.6	0